Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 2 Jun 2015 |
| Zealand presents to investors at four conferences in June 2015 | 29 May 2015 |
| Zealand Interim Report for Q1 2015 (unaudited) Increase in royalty revenue and progression of the development pipeline | 22 May 2015 |
| Zealand starts clinical development of a multiple-dose version of its stable glucagon analogue, ZP4207 | 20 May 2015 |
| Notice of Zealand’s Interim Report for Q1 2015 and related conference call | 13 May 2015 |
| Zealand announces an amendment to its Articles of Association following grant of warrants | 13 May 2015 |